Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
CHARCOAL, ACTIVATED
Oxford Pharmaceuticals Ltd
50 Grams
Oral Suspension
2001-11-16
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Liqui-Char Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Activated charcoal USP 25 g and 50 g unit dose packs. 3 PHARMACEUTICAL FORM Oral suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Poisoning, including drug overdose 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults (including the elderly)_: 50g, repeated if necessary _Children under 12 years_: Dosage should be adjusted according to the weight and age of the patient. Generally 25g should be given and repeated if necessary, although in cases where a large quantity of toxicant has been ingested or there is a risk to life, an initial dose of 50g is recommended. Liqui-Char should be given as soon as possible after the ingestion of the toxicant. In severe cases of poisoning or where sustained release drugs are involved, absorption of the toxicant may be prolonged and even the delayed administration of Liqui-Char may be beneficial. Repeated administration may be used to enhance the elimination of some toxic substances by preventing their re- absorption following active secretion in bile or their diffusion back into the gut from the circulation. The tube should be kneaded and shaken thoroughly before use. The tip should be carefully cut and the suspension may then be squeezed into a container for the patient to drink or administered through a gastric tube using the adapter provided. 4.3 CONTRAINDICATIONS None, but refer to “precautions” and “interactions” sections for inappropriate use. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Before administration, it should be confirmed the patient is breathing and any potential obstructions such as food or false teeth should be removed from the mouth. If ipecacuanha or any Izlasiet visu dokumentu